List of Excipients in Branded Drug VENOFER (IRON SUCROSE)

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
HF Acquisition Co LLC DBA HealthFirst	VENOFER (IRON SUCROSE)	venofer (iron sucrose)	51662-1568	WATER

Venofer Iron Sucrose Excipient Strategy and Commercial Opportunities

Last updated: August 5, 2026

Venofer is an established, off-patent intravenous iron product containing iron sucrose, sodium hydroxide, and water for injection. Its commercial opportunity is not based on a conventional small-molecule excipient patent strategy. The strongest opportunities are differentiated injectable presentations, improved physicochemical stability, reduced administration burden, container compatibility, and manufacturing advantages that preserve the iron-carbohydrate complex. The principal barriers are FDA comparability expectations, control of labile iron, particulate risk, and the need to demonstrate equivalent clinical performance in a crowded generic market.

What excipients are used in Venofer?

Venofer contains iron sucrose at a concentration of 20 mg/mL of elemental iron. The labeled inactive ingredients are sodium hydroxide and water for injection. Sodium hydroxide adjusts the formulation to an alkaline pH, reported in the U.S. prescribing information as approximately pH 10.5 to 11.1. The product does not rely on a conventional preservative, surfactant, sugar, amino acid, or chelating excipient system. [1]

Formulation attribute	Venofer profile
Active pharmaceutical ingredient	Iron sucrose
Elemental iron concentration	20 mg/mL
Primary excipients	Sodium hydroxide; water for injection
Dosage form	Intravenous solution
Typical presentations	50 mg/2.5 mL, 100 mg/5 mL, 200 mg/10 mL
Route	Intravenous injection or infusion
pH	Approximately 10.5-11.1
Preservative	None identified in the U.S. label
Container	Single-dose vial
Therapeutic category	Intravenous iron replacement
Reference product sponsor	Vifor, now within CSL’s Vifor business

The formulation is intentionally simple. Iron sucrose is a polynuclear iron(III)-oxyhydroxide core surrounded by sucrose molecules. The product is a colloidal iron-carbohydrate complex rather than a freely dissolved molecular iron salt. Excipients therefore influence complex stability, pH, osmolality, oxidation state, aggregation, container interaction, and free-iron release.

What excipient strategy is technically appropriate for iron sucrose?

The most defensible strategy is conservative excipient engineering. A new excipient should solve a measurable formulation or manufacturing problem without materially changing the iron sucrose complex.

pH control

Alkaline pH is central to Venofer’s formulation. Sodium hydroxide provides pH adjustment, but a developer could evaluate a low-capacity buffer or alternative alkali system to improve pH control during manufacture and storage.

The regulatory risk is substantial. Buffer species can interact with the iron-carbohydrate colloid, alter iron release, change osmolality, or affect infusion tolerability. A buffer substitution would require comparative testing covering:

• pH drift during accelerated and long-term stability;
• free and labile iron;
• molecular-weight distribution;
• iron-core structure;
• sucrose-to-iron relationship;
• particle-size distribution;
• visible and subvisible particulates;
• potency and total iron;
• container closure compatibility.

A buffer is commercially attractive only if it provides a clear benefit, such as lower batch-to-batch pH variability or improved stability after dilution.

Tonicity adjustment

Venofer does not depend on a separate tonicity agent in the labeled formulation. Sodium chloride may be relevant in diluted infusion admixtures, but adding sodium chloride directly to a ready-to-use product could change osmolality, ionic strength, and complex behavior.

A new isotonic presentation could have value for outpatient infusion centers if it reduces dilution steps. The formulation would need to show that the added ionic load does not increase aggregation, precipitation, or free-iron release.

Surfactants and anti-aggregation excipients

Polysorbates, poloxamers, and other surfactants are common in biologic products, but they are not automatically suitable for iron sucrose. Surfactants could affect the colloidal surface, iron-carbohydrate interactions, extractables, oxidation, and compatibility with infusion equipment.

A surfactant strategy has a higher probability of supporting a patentable product if it solves a specific problem, such as:

• reduced surface-induced aggregation;
• improved stability in a polymer syringe;
• lower particulate formation during shipping;
• longer in-use stability after vial puncture;
• compatibility with an autoinjector or closed-system transfer device.

The formulation should not add a surfactant merely to create a composition claim. The value must come from a demonstrated stability or delivery advantage.

Antioxidants and chelators

Antioxidants and chelators are technically sensitive in an iron product. A chelator can bind released iron, but it can also alter iron availability and pharmacology. Reducing agents may affect the oxidation state of iron or the carbohydrate matrix. These excipients may create more regulatory risk than commercial benefit unless the product has a defined oxidative-degradation problem.

A safer development path is often control of dissolved oxygen, headspace, container materials, light exposure, and manufacturing hold times before adding a chemically active excipient.

Polyols, sugars, and amino acids

Sucrose is part of the active iron-carbohydrate complex. Adding another sugar, polyol, or amino acid could improve freeze-thaw or interfacial stability, but such additions may complicate the product’s characterization and dilute the simplicity that supports generic development.

These excipients are more relevant to a differentiated presentation, such as a concentrated product, a premixed infusion bag, or a formulation designed for a device. Their value depends on whether they improve a commercially important attribute without changing the iron sucrose complex.

What commercial opportunities exist for Venofer excipients?

The largest opportunities are not likely to come from selling a single replacement excipient. They are more likely to arise from formulation packages, container systems, and manufacturing processes.

Opportunity	Commercial benefit	Technical hurdle	Patent potential
Ready-to-use infusion formulation	Reduces pharmacy preparation	Stability after dilution and container contact	Moderate
Improved vial formulation	Extends shelf life or lowers particulates	Complex characterization	Moderate
Polymer-compatible presentation	Supports prefilled syringe or closed system	Extractables, adsorption, silicone interaction	Moderate to high
Low-volume concentrated product	Reduces administration volume	Osmolality and tolerability	Moderate
Premixed saline bag	Simplifies infusion workflow	Long-term bag stability	Moderate
Preservative-free multi-dose concept	Reduces waste	Sterility and antimicrobial control	Low to moderate
Lyophilized iron sucrose	Enables distribution or storage advantages	Reconstitution and complex integrity	Moderate
Manufacturing excipient system	Improves yield and consistency	Process validation and comparability	Moderate to high
Low-particulate formulation	Supports institutional procurement	Analytical proof and control strategy	Moderate
Device-compatible formulation	Enables differentiated delivery	Human factors and combination-product review	High

Ready-to-use infusion bags

A premixed iron sucrose infusion product could reduce pharmacy compounding, preparation errors, and chair time. The commercial challenge is that Venofer is commonly diluted in normal saline before infusion. A product that eliminates dilution must demonstrate stability in the selected bag, tubing, ports, and transfer components.

The most relevant excipient questions are whether saline concentration, buffer capacity, bag material, and oxygen exposure affect the iron complex. The product could be positioned for hospitals, dialysis centers, ambulatory infusion providers, and specialty pharmacies.

Prefilled syringes and closed-system delivery

A prefilled syringe could reduce vial waste and simplify administration. The formulation would need compatibility with silicone oil, elastomer components, syringe barrels, needle shields, and terminal sterilization constraints.

The excipient opportunity is linked to surface stability. A formulation that limits adsorption or particle formation in a prefilled device could support a combination-product strategy. The relevant intellectual property may cover the formulation, the container closure, the fill volume, the device, or the use of the product in a defined administration system.

Low-volume or high-concentration products

Venofer is supplied at 20 mg/mL. A higher-concentration product could reduce infusion volume and improve logistics. The principal risks are increased osmolality, local tolerability, vascular irritation, and altered iron release.

A high-concentration product would need a clear clinical or operational advantage. Concentration alone is unlikely to establish durable differentiation if generic sponsors can reach the same concentration through routine formulation work.

Stability after dilution

A formulation that remains stable for longer periods after dilution could reduce pharmacy waste and permit centralized preparation. A useful product claim could involve stability for a defined time in a specified diluent, container, temperature range, and light condition.

This opportunity is stronger when supported by a validated analytical package covering labile iron, particle formation, iron sucrose integrity, potency, and container compatibility. A claim based only on visual appearance would be commercially weak.

What patents protect Venofer and iron sucrose formulations?

Venofer’s original composition and product exclusivity are no longer the primary commercial barrier. The product has been marketed for more than two decades, and iron sucrose is available from multiple generic manufacturers. FDA’s Orange Book remains the relevant source for listed patents and regulatory exclusivity associated with the reference drug. [2]

Orange Book and exclusivity position

Issue	Venofer position
Reference product	Venofer
Active ingredient	Iron sucrose
U.S. approval pathway	NDA product
Core market status	Mature and off-patent
Generic competition	Established
Biosimilar pathway	Generally not the principal pathway
Orange Book relevance	Listed patents and exclusivity, if any, must be checked against the current FDA entry
Commercial protection	Primarily manufacturing scale, supply reliability, contracts, and product differentiation

Iron sucrose is a complex iron-carbohydrate product. Generic approval does not depend solely on the type of small-molecule sameness analysis used for a conventional tablet. FDA has issued product-specific guidance for iron sucrose injection and evaluates qualitative and quantitative sameness, pharmaceutical equivalence, and relevant characterization data. [3]

A new excipient formulation could create protection around:

• a defined iron-to-excipient ratio;
• a pH range;
• a narrow free-iron specification;
• a particle-size or molecular-weight distribution;
• a dilution-stability profile;
• a container closure system;
• a ready-to-use infusion product;
• a method of reducing particulates;
• a manufacturing hold or mixing sequence;
• a device-compatible formulation.

A patent directed only to sodium hydroxide replacement may be vulnerable to design-around. A stronger estate would combine composition, process, container, method-of-use, and presentation claims.

When does Venofer lose exclusivity?

Venofer has already lost practical market exclusivity in the United States. The relevant commercial question is not the date of original patent expiry but whether a new formulation or presentation can create a separate period of enforceable protection.

For a new iron sucrose product, potential protection may come from:

1. New formulation patents.
2. Device or container patents.
3. Manufacturing-process patents.
4. Method-of-use patents tied to a specific dosing regimen or patient population.
5. Regulatory exclusivity associated with a qualifying new clinical investigation.
6. Contractual supply arrangements and institutional purchasing positions.

A formulation patent can be commercially useful even when the active ingredient is generic, but enforcement depends on whether competing products necessarily practice the claimed excipient system. Narrow claims that cover an optional excipient are less powerful than claims tied to a measurable product attribute that competitors must reproduce.

What generic entry risks exist for a new Venofer excipient formulation?

Generic entry risk is high because iron sucrose is an established product with an existing supplier base. A new excipient formulation faces five principal risks.

Routine design-around

A competitor may use a different pH adjuster, buffer, concentration, container, or manufacturing sequence. Claims should therefore avoid unnecessary dependence on one excipient name when the commercial objective can be captured through functional or product-property limitations.

FDA comparability complexity

Iron sucrose is a complex mixture or colloidal product. FDA expects extensive characterization. A new excipient may change the product enough to require a full development program rather than a straightforward generic pathway.

Clinical differentiation requirements

If the product claims better tolerability, faster administration, fewer hypersensitivity reactions, or improved outcomes, clinical evidence may be required. Excipient-driven claims that remain limited to stability or handling are generally easier to develop than clinical superiority claims.

Supply substitution

Hospitals and dialysis providers may substitute between Venofer and generic iron sucrose when the labeled composition and administration requirements are similar. A new product needs a measurable workflow or cost advantage.

Purchasing concentration

The U.S. market is heavily influenced by large dialysis providers, group purchasing organizations, hospital systems, and national distributors. A technically superior excipient system may fail commercially if it increases acquisition cost without reducing labor, waste, or chair time.

How does Venofer compare with competing intravenous iron products?

Venofer competes with both generic iron sucrose and other intravenous iron products. Excipient strategy must be evaluated against the full treatment alternative, not only against Venofer.

Product	Active iron form	Typical differentiation	Excipient opportunity
Venofer	Iron sucrose	Established use, lower-dose administration	Workflow, dilution, device compatibility
Ferrlecit	Sodium ferric gluconate complex	Alternative iron-carbohydrate complex	Comparative tolerability and administration
Injectafer	Ferric carboxymaltose	Larger-dose administration	Less relevant to direct excipient substitution
Monoferric	Ferric derisomaltose	High-dose replacement	Competes on dosing convenience
Generic iron sucrose	Iron sucrose	Price and supply	Cost, quality, low particulates, packaging

Venofer’s strongest defense is clinical familiarity and broad institutional use. Its weakness is administration burden relative to high-dose iron products. An excipient-based product that only matches Venofer will compete primarily on price. A product that reduces preparation, dilution, waste, or infusion time has a stronger commercial position.

What regulatory pathway applies to a new iron sucrose excipient product?

The pathway depends on the degree of change.

Generic iron sucrose

A product intended to be therapeutically equivalent to Venofer generally follows an abbreviated application strategy. The sponsor must address pharmaceutical equivalence, qualitative and quantitative formulation requirements, manufacturing controls, and product-specific characterization. FDA’s iron sucrose guidance is central to development planning. [3]

New formulation or presentation

A materially different excipient system, ready-to-use bag, prefilled syringe, or device-linked product may require a 505(b)(2) strategy or another full NDA-based approach, depending on the formulation and claims. The sponsor would need to establish that the new presentation remains clinically appropriate and does not alter the therapeutic behavior of the iron complex.

Regulatory testing priorities

The core analytical package should include:

• elemental iron assay;
• total iron and labile iron;
• sucrose content and degradation products;
• iron-core characterization;
• particle-size distribution;
• molecular-weight distribution;
• pH and osmolality;
• visible and subvisible particulates;
• sterility and bacterial endotoxins;
• extractables and leachables;
• dilution and in-use stability;
• container closure integrity.

Which excipient patents have the strongest commercial value?

The strongest patent programs will connect the excipient to a required commercial outcome.

High-value claim themes

• A stable iron sucrose composition at a defined concentration and pH.
• A low-particulate formulation compatible with a prefilled syringe.
• A premixed infusion product stable in a specified bag material.
• A formulation with extended post-dilution stability.
• A manufacturing process that produces a defined iron-carbohydrate distribution.
• A formulation that remains stable under shipping stress and repeated temperature excursions.
• A container system that reduces adsorption, oxidation, or particle generation.

Lower-value claim themes

• A broad list of optional pharmaceutically acceptable excipients.
• A generic replacement of sodium hydroxide with another base.
• A formulation claim without defined product-property limits.
• A stability claim based only on appearance.
• A use claim that does not change dosing, administration, or patient selection.

What licensing and partnership opportunities exist?

The most practical licensing targets are excipient suppliers with injectable-grade materials, pharmaceutical packaging companies, contract development and manufacturing organizations, and device manufacturers.

Potential partnership structures include:

• exclusive rights to a low-particulate excipient system;
• co-development of a ready-to-use iron infusion bag;
• licensing of a prefilled syringe platform;
• supply agreements for specialized elastomers or polymer containers;
• manufacturing licenses for iron sucrose complex formation;
• regional rights for hospital or dialysis channels.

The partner must contribute more than a commodity excipient. A defensible deal requires formulation know-how, analytical methods, manufacturing controls, or a protected container and delivery system.

How strong is the Venofer iron sucrose patent estate?

The core Venofer estate is commercially weak as a barrier to generic competition because iron sucrose is mature, widely marketed, and available from multiple suppliers. The more relevant IP question concerns new presentations and manufacturing controls.

Estate component	Relative strength
Original iron sucrose composition	Low for current market exclusion
Basic sodium hydroxide/water formulation	Low
Generic iron sucrose manufacturing know-how	Moderate if difficult to reproduce
Low-particulate formulation	Moderate
Premixed infusion presentation	Moderate
Prefilled syringe and container system	Moderate to high
Defined complex characterization profile	Moderate
New dosing or patient-selection method	Variable
Supply and contracting position	Commercially important but not patent protection

Key Takeaways

• Venofer uses a minimal formulation: iron sucrose, sodium hydroxide, and water for injection.
• The product is off-patent in practical commercial terms, with established generic competition.
• The best excipient opportunities involve ready-to-use presentations, dilution stability, container compatibility, particulate control, and manufacturing consistency.
• Surfactants, antioxidants, and chelators require caution because they can alter the iron-carbohydrate complex.
• A new formulation may require a 505(b)(2) or other NDA-based strategy if it materially departs from the reference product.
• Patent value will be higher when claims cover a required product attribute, manufacturing result, container system, or device combination.
• Generic entry risk is high for products that offer only a minor excipient substitution.
• Commercial differentiation should target pharmacy labor, infusion-center throughput, waste reduction, shelf life, and supply reliability.

FAQs

Can sodium hydroxide in Venofer be replaced with another pH adjuster?

Yes, technically, but replacement would require comparative evidence that the new base does not change pH stability, iron release, particle formation, osmolality, or the physicochemical profile of iron sucrose.

Can Venofer be reformulated as a preservative-containing multidose vial?

A multidose presentation would require antimicrobial effectiveness, sterility, container closure, and compatibility data. The addition of a preservative could introduce toxicity and iron-complex interaction risks.

Is a premixed Venofer infusion bag a viable commercial product?

Yes. A premixed bag could reduce pharmacy preparation and waste. The main development issues are stability in the selected bag, tubing and port materials, dilution conditions, particulate control, and reimbursement.

Can an excipient patent block generic iron sucrose?

It can block a generic only if the generic product practices valid, enforceable claims. A narrow claim to an optional excipient may be easy to design around. Claims tied to a necessary container system, process result, or product-property profile are stronger.

Are biosimilars the main competitive threat to Venofer?

No. The primary competitive threat is generic iron sucrose and alternative intravenous iron products. Biosimilar concepts are less central because iron sucrose is a non-biologic complex product rather than a conventional therapeutic biologic.

References

1. U.S. Food and Drug Administration. (2023). Venofer (iron sucrose) injection, prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2013). Iron sucrose injection: Product-specific guidance for industry.
4. United States Pharmacopeia. (2024). Iron sucrose injection and general chapters for injectable drug products. USP–NF.
5. U.S. Food and Drug Administration. (2022). Guidance for industry: Drug products, including biological products, that contain nanomaterials.